Clinicians from the research institute that helped discover venetoclax (Venclexta) have welcomed its listing on the PBS for people with relapsed or refractory chronic lymphocytic leukaemia (CLL). From 1 March 2019, venetoclax will be subsidised in combination with rituximab for the treatment of certain patients with relapsed or refractory chronic lymphocytic leukaemia who have received ...
Venetoclax gets PBS listing for CLL
By Michael Woodhead
25 Feb 2019